A follow-up study targeting NKp30 on NK cells and EGFR on tumor cells used a BiKE construct combining NKp30-specific VHH of Camelidae origin and the EGFR-specific humanized Fab of cetuximab, leading to a more potent NK-cell-mediated tumor-killing effect in vitro when compared to the previous B7-H6 construct or cetuximab treatment [99]. The gene discussed is NCR3; the disease is neoplasm.